Literature DB >> 28456499

[Use of resources and costs associated with non-adherence to inhaled corticosteroid treatment in asthma].

A Sicras-Mainar1, A Huerta2, D Sánchez3, R Navarro-Artieda4.   

Abstract

OBJECTIVE: To estimate adherence to asthma treatment with inhaled corticosteroid in clinical daily practice, and its relationship with exacerbations, as well as its use of resources and costs.
MATERIAL AND METHODS: An observational, retrospective study using the electronic medical records of the Badalona Health Service provider. The study included patients≥15 years old with a confirmed diagnosed of asthma, and who initiated treatment with an inhaled corticosteroid between January 2010 and December 2011. The follow-up period was 24 months. Adherence to treatment was measured using the medication possession ratio. Two groups were established: adherent (ADH; medication possession ratio≥80%) and non-adherent (non-ADH; medication possession ratio<80%) patients. The main demographic and clinical variables, including exacerbations, were collected, along with the healthcare and non-healthcare (days of absence from work) resource use, and costs.
RESULTS: The study included a total of 2,303 patients, with a mean age of 48.6 years, and 64.3% females. Just over half (52.6%) of the patients had moderate persistent asthma, and 51.0% of patients adhered to treatment. In the non-ADH patients, 63.4% suffered at least one exacerbation in the follow-up period, compared with 37.4% of the adherent patients (P<.001). The non-ADH patients also consumed a higher percentage of healthcare resources in Primary Care (22.5 vs. 17.4%), secondary care (3.3 vs. 2.5%), and emergency visits (1.4 vs. 0.2%) during the follow-up period (P<.001 in all cases). No statistical significance differences were observed in the days of absence from work. Mean annual cost of non-ADH patients was 1,431€/patient, compared with 722€/patient (P<.001) of ADH patients.
CONCLUSION: Lack of adherence was associated with an increase in exacerbation rates, as well as healthcare resource consumption and costs.
Copyright © 2017 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Adherence; Adherencia; Asma; Asthma; Corticoides inhalados; Costes; Costs; Inhaled corticosteroids

Mesh:

Substances:

Year:  2017        PMID: 28456499     DOI: 10.1016/j.semerg.2017.03.005

Source DB:  PubMed          Journal:  Semergen        ISSN: 1138-3593


  3 in total

Review 1.  Measuring Medication Adherence in a Population-Based Asthma Administrative Pharmacy Database: A Systematic Review and Meta-Analysis.

Authors:  Michael Asamoah-Boaheng; Kwadwo Osei Bonsu; Jamie Farrell; Alwell Oyet; William K Midodzi
Journal:  Clin Epidemiol       Date:  2021-10-22       Impact factor: 4.790

2.  Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study.

Authors:  Antoni Sicras-Mainar; Belén Gómez Rodríguez; Susana Traseira-Lugilde; Toni Fernández-Sánchez; José Luis Velasco Garrido
Journal:  BMJ Open       Date:  2022-04-20       Impact factor: 3.006

3.  Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma.

Authors:  Laura Amanda Vallejo-Aparicio; Jesús Molina; Iñigo Ojanguren; Ana Viejo Casas; Alicia Huerta; Henrik Svedsater
Journal:  Eur J Health Econ       Date:  2019-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.